ClinicalTrials.gg
Not yet recruitingNCT07309380Updated Oct 28, 2026

Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

A Phase 3 interventional study of Hepalatide 2.1mg and Placebo of Hepalatide in Hepatitis D, Chronic, sponsored by Shanghai HEP Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Shanghai HEP Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D.

A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randomly assigned to the L47 group or the placebo group at a ratio of 2:1, with liver cirrhosis and subjects' regional distribution as stratification factors. The two groups will receive hepratide (2.1 mg/day) or placebo, respectively. Upon completion of the 48-week double-blind treatment phase, all subjects in each group can enter the open-label treatment follow-up phase, where they may voluntarily choose to receive L47 (2.1 mg/day) treatment or undergo follow-up observation only, until week 144.

Subjects who discontinue treatment prematurely during the trial may also enter the open-label treatment follow-up phase.

An interim analysis will be conducted after the subjects complete 24 weeks of trial treatment, with the comprehensive response rate at week 24 as the primary endpoint. The analysis will be performed by an independent statistical team. And the interim analysis results will be reviewed by the Independent Data Monitoring Committee (IDMC) .

All subjects will complete the 48-week double-blind clinical trial. Throughout the entire study period, the safety of subjects will be closely monitored and evaluated, including the monitoring of adverse events (AEs) and other safety indicators.

02

Conditions studied

  • Hepatitis D, Chronic

Browse trials for

Keywords

  • hepalatide
  • L47
03

In context

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

This study's planned enrollment of 150 is above the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.

Browse Hepatitis D, Chronic studies →

Lead sponsor

Shanghai HEP Pharmaceutical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive or HBV DNA for at least 6 months (diagnosed as chronic hepatitis B), with stable nucleos(t)ide analogue (NA) treatment for ≥3 months prior to screening and documented HBV DNA suppression;
  • Positive anti-HDV antibody (IgG and/or IgM) and at least two quantifiable HDV RNA measurements ≥3 months apart, with quantifiable HDV RNA at enrollment;
  • 1×\< \<10×ULN;
  • No plan for pregnancy within 2 years; female subjects must not be pregnant or lactating, and all subjects must agree to use effective during treatment and for 3 months after the last dose;
  • No participation in other clinical trials within 3 months prior to screening;
  • Good compliance with the study protocol;
  • Ability to understand and willingness to sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

  • class C or Child-Pugh score ≥10;
  • Subjects with any of the following conditions:

    1. History of severe decompensated liver disease, including moderate to severe ascites (grade 2 or 3), hepatic encephalopathy, gastrointestinal variceal bleeding, hepatorenal syndrome, etc., with an expected survival of less than 2 years;
    2. History of severe cardiac disease (including unstable or uncontrolled heart disease within the past 6 months, or [NYHA] functional class III-IV);
    3. Uncontrolled epilepsy, severe psychiatric disorders, or a history of severe psychiatric disorders;
    4. History of organ transplantation;
    5. Diabetes mellitus or hypertension that is not adequately controlled;
    6. Presence of diseases, immune-related extrahepatic manifestations (including vasculitis, purpura, polyarteritis nodosa, peripheral neuropathy, and glomerulonephritis), thyroid diseases, , or receipt of therapy;
    7. Presence of serious underlying diseases such as severe infection, heart failure, , or other serious diseases;
    8. History of alcohol abuse or drug addiction.
  • Total > 51 μmol/L, or serum albumin \< 28 g/L, or prolonged by > 6 seconds;
  • \<60mL/min;
  • Co-infection with hepatitis A, C, or E virus, or infection;
  • Use of interferon within 3 months prior to screening;
  • Positive pregnancy test in female subjects;
  • Abnormal hematology results: white blood cell count (WBC) \< 3×10\^9/L, 1.5×10\^9/L, or count 60×10\^9/L;
  • Current use of prohibited medications that cannot be discontinued;
  • Use of L47 or Myrcludex B within 3 months prior to screening;
  • Subjects receiving standardized nucleos(t)ide analogue (NA) therapy with a treatment duration of less than 12 weeks;
  • Other significant abnormalities in laboratory tests or auxiliary examinations that, in the opinion of the investigator, make the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Placebo comparator
    Group A

    placebo of L47, sc,qd

    Drug: Placebo of Hepalatide

  • Experimental
    Group B

    hepalatide 2.1mg, sc, qd, Continuous treatment for 48 weeks

    Drug: Hepalatide 2.1mg

Interventions

  • Continuous treatment with hepalatide 2.1mg sc, qd, for 48 weeks

    Also known as: L47, HLT

  • DrugPlacebo of Hepalatide

    Continuous treatment with placebo of hepalatide for 48 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who achieved response

    HDV RNA suppression (\< LLOQ) or a decrease of ≥ 2 log10 from baseline combined with ALT normalization

    Time frame: 48 weeks of treatment

Secondary outcomes

  1. Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline

    Time frame: 48 weeks of treatment

  2. Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline and normalized ALT

    Time frame: Continuous treatment for 48 weeks

  3. Proportion of subjects with HDV RNA below the limit of detection (LOD)

    Time frame: Continuous treatment for 48 weeks

  4. Changes in HDV RNA relative to baseline

    Time frame: Continuous treatment for 48 weeks

  5. Proportion of subjects with normalized ALT

    Time frame: Continuous treatment for 48 weeks

  6. Changes in ALT relative to baseline

    Time frame: Continuous treatment for 48 weeks

  7. Changes in HBV-related parameters (HBV DNA, HBeAg, qHBsAg, etc.)

    Time frame: Continuous treatment for 48 weeks

  8. Changes in histological response of the liver

    Time frame: Continuous treatment for 48 weeks

  9. Change in Model for End-Stage Liver Disease (MELD) score

    Time frame: Continuous treatment for 48 weeks

  10. Change in Child-Turcotte-Pugh score

    Time frame: Continuous treatment for 48 weeks

  11. Occurrence of liver-related endpoint events

    such as cirrhosis, hepatic decompensation, HCC, liver transplantation / liver-related death, etc.

    Time frame: continuous treatment for 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Jun 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Apr 2026 → Jun 2027, primary completion Jun 2027 → Jun 2028 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartEst.
Jun 2027was Apr 2026
Primary completionEst.
Jun 2028was Jun 2027
CompletionEst.
Aug 2028was Aug 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Jun 2027
Oct 28, 2026
Primary completion
Jun 2027→Jun 2028
Oct 28, 2026
Study completion
Aug 2027→Aug 2028
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date Apr 2026→Jun 2027
    Primary completion Jun 2027→Jun 2028
    Study completion Aug 2027→Aug 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07309380
Lead sponsor
Shanghai HEP Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Jun 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Xiaolu Tang
Contact
tangxiaolu@heppharma.com
86-21-68412368
Xian Gao
Contact
gaoxian@heppharma.com
Junqi Niu, Professor
study chair · The First Hospital of Jilin University
Yanhang Gao
study chair · The First Hospital of Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepalatide

Start the discussion